



ATTORNEY'S DOCKET NO. H00498/70162 TIO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gavin MacBeath et al.
Serial No: 09/923,243
Confirmation No.: 9118
Filed: August 3, 2001
For: PROTEIN MICROARRAYS
Art Unit: 1619

RECEIVED
APR 07 2002
TECHNICAL CENTER 1600/2800
5/

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 18th day of March 2002.

Signature

Commissioner for Patents
Washington, D. C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

In the Specification

Please rewrite the specification below as shown. A marked-up version of the rewritten specification is attached hereto illustrating these changes.

Please rewrite paragraph 2 on page 30 (beginning at line 9) as follows:

Screening for competitors of ligand binding (Figure 8). SuperAldehyde slides were coated at room temperature with a solution of "5-helix" dissolved in phosphate buffered saline, pH 7.5 (PBS), at a concentration of 0.1 mg/ml. "5-helix" is a portion of the HIV protein gp41 and has been previously described by Root *et al.* in *Science* 291:884-888, 2001; which is incorporated herein by reference. After 1 hour, the slides were immersed in a solution of PBS/Tween-20 (0.1%) [PBST] + 1% BSA, at room temperature for one hour to quench all the unreacted sites on the slide. After 1 hour, the slides were rinsed with PBST and then incubated for 1 hour at room temperature with either 10 nM of C37-H6 (GGHTTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLGGHHHHHH) (SEQ ID NO:1), 1 μ m or 10 nM JN-DCC1 (GGHTTWMEWDREINNYTSLIHSLEESQNQQEKNEQELL) (SEQ